Advances in invasive micropapillary carcinoma of the breast research: A review

Li-hao Cheng,Xiao-jie Yu,Hao Zhang,Hao-Jie Zhang,Zhongming Jia,Xiao-hong Wang
DOI: https://doi.org/10.1097/md.0000000000036631
IF: 1.6
2024-01-11
Medicine
Abstract:Invasive Micropapillary Carcinoma (IMPC) of the breast represents a rare subtype of invasive breast carcinoma, first introduced by Fisher et al in 1980 [ 1 ] and was renamed IMPC in 1993. Morphologically, the cancerous cells are distributed along micropapillae or mulberry-like structures that lack a fibrovascular core. Clinically, IMPC shows notable malignant characteristics like a significant lymphovascular invasion (LVI) and regional lymph node metastasis (LNM). [ 2 ] In 2003, the World Health Organization characterized IMPC as a unique pathological subtype of breast tumors. [ 3 ] Thus, IMPC exhibits a heightened level of malignancy when compared with conventional invasive breast carcinomas. This is duly characterized by increased LNM and LVI rates which imply a poorer prognosis. Several biomarkers, such as KL-67, MUC1, and EMA are associated with the pathological progression and prognosis of IMPC. Particularly, MUC1, whose aberrant expression is linked to tumor proliferation and LNM. Other receptor molecules like sLex and CXCR4 are implicated in tumor immune evasion mechanisms. Additionally, a few proteins like plakoglobin, LEF1, and ARID1A help in IMPC progression. Multiple working mechanisms and signaling pathways influencing IMPC progression are cell cycle regulation, metabolic abnormalities, and protein kinase signaling routes. This review aimed to evaluate cutting-edge research developments concerning IMPC and shed light on its intricate biological as well as therapeutic avenues.
medicine, general & internal
What problem does this paper attempt to address?